Physiological Barriers, System Design, and Applications in Disease Prevention and Treatment for Local mRNA Delivery to the Respiratory Tract
MedComm – Biomaterials and Applications · 2026-12 · 5 (4)
DOI: 10.1002/mba2.70083 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm – Biomaterials and Applications, online erschienen am 16.11.2026. Verfasst von Longwei Xiang und 3 weiteren Autor:innen. Die Arbeit nennt 208 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Messenger RNA (mRNA) therapies enable transient, controllable, and programmable protein expression without integrating into the host genome. However, pulmonary mRNA delivery remains constrained by airway deposition, mucociliary clearance, mucus entrapment, pulmonary surfactant interactions, extracellular nuclease degradation, nonspecific immune‐cell uptake, and inefficient endosomal escape. This review systematically examines local pulmonary mRNA delivery through a three‐tier barrier framework encompassing airway clearance, the alveolar microenvironment, and intracellular trafficking, and further discusses how disease‐specific pathological microenvironments remodel these barriers. We compare major non‐viral delivery platforms, including lipid nanoparticles, polymeric nanoparticles, liposomes, micelles, and extracellular vesicles, with emphasis on their molecular design, physicochemical properties, nebulization stability, mucus penetration, intracellular release, and translational limitations. Representative applications in protein replacement, mucosal vaccination, lung cancer immunotherapy, and inflammatory and fibrotic lung diseases are also summarized. Particular emphasis is placed on three interconnected dimensions: maintaining formulation stability during nebulization, adapting delivery systems to disease‐remodeled pulmonary barriers, and achieving cell‐selective mRNA delivery. Finally, we discuss pulmonary safety, repeated administration, disease‐relevant functional outcomes, and preclinical‐to‐clinical translation. By integrating barriers, carrier design, therapeutic applications, and translational considerations, this review provides a framework for the rational development of safe, reproducible, and clinically meaningful pulmonary mRNA therapies.
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Xiang, L., You, Y., Hao, K., & Tian, H. (2026). Physiological Barriers, System Design, and Applications in Disease Prevention and Treatment for Local mRNA Delivery to the Respiratory Tract. MedComm – Biomaterials and Applications, 5(4). https://doi.org/10.1002/mba2.70083
Vancouver
Xiang L, You Y, Hao K, Tian H. Physiological Barriers, System Design, and Applications in Disease Prevention and Treatment for Local mRNA Delivery to the Respiratory Tract. MedComm – Biomaterials and Applications. 2026;5(4). doi:10.1002/mba2.70083
BibTeX
@article{Xiang2026,
author = {Xiang, Longwei and You, Yunni and Hao, Kai and Tian, Huayu},
title = {Physiological Barriers, System Design, and Applications in Disease Prevention and Treatment for Local mRNA Delivery to the Respiratory Tract},
journal = {MedComm – Biomaterials and Applications},
year = {2026},
volume = {5},
number = {4},
doi = {10.1002/mba2.70083}
}
EUVIMED